BRM's, Increased risk of fungal infections
Posted: Tue Sep 16, 2008 8:23 pm
http://www.fda.gov/bbs/topics/news/2008/new01879.html
new FDA labeling requirement for Biological Response Modifying drugs to note that there is an Increased risk of serious fungal infections.
"Patients taking TNF blockers should be aware that they are more susceptible to serious fungal infections. Those who develop a persistent fever, cough, shortness of breath, and fatigue should promptly seek medical attention. To assist in the diagnosis, those being treated with TNF blockers should tell their health care professionals where they live and what areas they have recently visited. Patients who develop a fungal infection may be advised to stop the TNF blocker until they recover"
new FDA labeling requirement for Biological Response Modifying drugs to note that there is an Increased risk of serious fungal infections.
"Patients taking TNF blockers should be aware that they are more susceptible to serious fungal infections. Those who develop a persistent fever, cough, shortness of breath, and fatigue should promptly seek medical attention. To assist in the diagnosis, those being treated with TNF blockers should tell their health care professionals where they live and what areas they have recently visited. Patients who develop a fungal infection may be advised to stop the TNF blocker until they recover"